Home
Duchenne
Categories
Care Guidelines
Press Releases
Approved Therapies
Researches
Editorials
Family Stories
Our Tools
Exon Check Tool
Clinical Trials
Active Studies
Trial Statistics
Trials Map
Pipeline
Search
About Us
Contact
APPs
Privacy Policy
type here...
Search
Instagram
Facebook
Twitter
Bluesky
Home
Duchenne
Duchenne MD
What is Duchenne?
Genetic Causes
Creatine Kinase (CK)
Genetic Testing
Prenatal Testing
Becker MD
DMD vs BMD
NSAA Assessment
Genetic
Genetic Counseling
Dystrophin Gene
Genetic Variants
Exon Deletion
Duchenne Carriers
Nucleotides in DMD
Isoforms in DMD
What is Exon Skipping
Care Guidelines
Newly Diagnosed
Neuromuscular Team
Respiratory Devices
BiPAP Machine
Ankle Foot Orthosis
Rhabdomyolysis
Power Wheelchair
Traveling with DMD
Health Guidelines
Psychological Support in DMD
Nutrition in DMD
Nutraceuticals
Respiratory Health
Dental Health
Surgery & Anesthesia
Swallowing Difficulty
Steroids (Cortisone)
Categories
Care Guidelines
Press Releases
Approved Therapies
Researches
Editorials
Family Stories
Our Tools
Exon Check Tool
Clinical Trials
Active Studies
Trial Statistics
Trials Map
Pipeline
WhatsAPP
Home
Tags
DYNE-251
DYNE-251
Editorials
7 Breakthrough DMD Research Programs That Could Transform Duchenne Treatment in 2026
Press Releases
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen, an Exon 51 Skipping Therapy for Duchenne Muscular Dystrophy (DMD)
Research
DYNE-251 Phase 3 FORZETTO Clinical Trial of Z-Rostudirsen Officially Begins for DMD
Press Releases
Dyne Therapeutics to Apply for Accelerated Approval in Q2 2026 for Exon 51 Skipping Therapy (DYNE-251)
Press Releases
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
Press Releases
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
Press Releases
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
Press Releases
Dyne Therapeutics Announces Unprecedented and Sustained Functional Improvement Through 18 Months from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy
Press Releases
Plans for DYNE-101 in DM1 and DYNE-251 in DMD Are Announced by Dyne Therapeutics
Popular
Frequently Asked Questions About Elevidys Used for DMD
Can Ekinci
-
August 21, 2026
Must Read
Editorials
CRISPR GuideX Tool: hfCas12Max in CRISPR-Based Therapeutics
Care Guidelines
Breathing Exercises in Duchenne Muscular Dystrophy: Respiratory Therapy, Pulmonary Care & Lung Support
Research
BioMarin Launches BMN 351 Exon 51 Skipping Therapy Phase 2 Clinical Trial for Duchenne Muscular Dystrophy